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TGF-beta has been shown to play critical roles in immune
suppression that occurs in cancer patients. TGF-beta has
three isoforms, TGF-beta1, 2 and 3. We and others have
reported that blockade of all three isoforms enhances
tumor immunosurveillance and cancer vaccine efficacy in
mouse tumor models. Among the three isoforms of TGF-
beta, TGF-beta1 and TGF-beta2, especially TGF-beta1,
have been widely studied for their suppressive activity on
T cell activation as well as their ability to induce immune
suppressive cells (e.g. Treg and MDSC). However, very lit-
tle is known about the function of TGF-beta3 in either
immunology or cancer although there are some studies
that suggest this isoform may have some beneficial activity
for cancer patients. Thus, in this study, we asked whether
it is necessary to block TGF-beta3 to enhance tumor
immunity by using monoclonal antibodies with different
specificities against TGF-beta isoforms. In a pulmonary
metastasis model of colon carcinoma CT26, blockade
solely of TGF-beta1 and TGF-beta2 but not TGF-beta3
significantly reduced tumor burden to a degree similar to
that achieved by blockade of all isoforms, suggesting that
it is not necessary to block TGF-beta3 to facilitate tumor
immunosurveillance. In a subcutaneous TC-1 model in
which a peptide based vaccine was administered to mice
with well established tumors (at least 5 mm in diameter),
TGF-beta blockade significantly enhanced vaccine efficacy
to reduce tumor size although blockade of TGF-beta alone
had no effect on tumor growth. Since blockade of only
TGF-beta1 and TGF-beta2 significantly improved vaccine
efficacy similarly to blockade of all isoforms, we concluded
that inhibition of TGF-beta3 is not necessary to enhance
the therapeutic tumor vaccine efficacy. Surprisingly block-
ade of TGF-beta did not change the number of MDSCs,
Th17 or Treg cells in tumors. It also did not change the
number of vaccine specific-CD8+ T cells. However, it
increased the number of T-bet expressing CD4+ and
CD8+ T cells, suggesting that more Th1-type T cells
infiltrated into tumors when TGF-beta was blocked. In
conclusion, blockade of TGF-beta1 and TGF-beta2 is
sufficient to enhance tumor immunity, and sparing
TGF-beta3 may be beneficial for patients.
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